Compound: Muraglitazar
SMILES: O=C(Oc1ccc(OC)cc1)N(Cc2ccc(OCCc3nc(-c4ccccc4)oc3C)cc2)CC(=O)O
InChIKey: IRLWJILLXJGJTD-UHFFFAOYSA-N
Synonyms: Muraglitazar, 331741-94-7, BMS-298585, W1MKM70WQI, BMS298585, DTXSID9057719, MK0478, MK-0478, BMS-298585-01, 2-[(4-methoxyphenoxy)carbonyl-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]amino]acetic acid, DTXCID0031508, N-((4-methoxyphenoxy)carbonyl)-N-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)glycine, N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine, 2-((4-methoxyphenoxy)carbonyl-((4-(2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy)phenyl)methyl)amino)acetic acid, muraglitazarum, RefChem:819616, 2-(((4-methoxyphenoxy)carbonyl)((4-(2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy)phenyl)methyl)amino)acetic acid, Pargluva, BMS 298585;Pargluva, CHEMBL186179, N-((4-Methoxyphenoxy)carbonyl)-N-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)glycine, Glycine, N-((4-methoxyphenoxy)carbonyl)-N-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)-, BMS 298585, Muraglitazar [USAN], UNII-W1MKM70WQI, Muraglitazar [USAN:INN], CCRIS 9258, (((4-Methoxyphenoxy)carbonyl)(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)amino)acetic acid, [[(4-Methoxyphenoxy)carbonyl][4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzyl]amino]acetic acid, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, MURAGLITAZAR [MI], Muraglitazar (USAN/INN), MURAGLITAZAR [INN], MURAGLITAZAR [MART.], MURAGLITAZAR [WHO-DD], SCHEMBL676469, orb1705016, CHEBI:188851, IRLWJILLXJGJTD-UHFFFAOYSA-N, C29H28N2O7, GLXC-15805, MSK11070, Tox21_113946, BDBM50150998, EX-A10674, MFCD20270627, AKOS030255656, DB06510, NCGC00262954-01, 2-(((4-methoxyphenoxy)carbonyl)(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)amino)acetic acid, 2-[(4-methoxyphenoxy)carbonyl-[[4-[2-(5-methyl-2-phenyl-oxazol-4-yl)ethoxy]phenyl]methyl]amino]acetic acid, HY-17445, TS-08171, CAS-331741-94-7, CS-0008241, NS00072609, D05091, H39694, [C14]-2-((4-methoxyphenoxy)carbonyl)acetic acid, Q6937233, ((4-Methoxy-phenoxycarbonyl)-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-amino)-acetic acid, 2-[(4-methoxyphenoxycarbonyl)({3-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl}methyl)amino]acetic acid, 2-[(4-methoxyphenoxycarbonyl)({4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl}methyl)amino]acetic acid, N-((4-METHOXYPHENOXY)CARBONYL)-N-((4-(2-(5-METHYL-2-PHENYL-4-OXAZOLYL)ETHOXY)PHENYL)-METHYL)GLYCINE, N-[(4-Methoxyphenoxy)carbonyl]-N-({4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl}methyl)glycine, N-[[4-methoxyphenoxy)carbonyl]-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)-ethoxy]phenyl]methyl]glycine
Theoretical properties:
molecular_formula: C29H28N2O7
molecular_weight: 516.5 g/mol
exact_mass: 516.18965124 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 8
rotatable_bond_count: 12
heavy_atom_count: 38
topological_polar_surface_area: 111 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Muraglitazar is a member of 1,3-oxazoles.
chembl: MURAGLITAZAR is a small molecule listed in the ChEMBL database and has reached clinical trial phase 3.0.
wikipedia: Muraglitazar (proposed tradename Pargluva) is a dual peroxisome proliferator-activated receptor agonist with affinity to PPARα and PPARγ.
The drug had completed phase III clinical trials, however in May 2006 Bristol-Myers Squibb announced that it had discontinued further development.
Data on muraglitazar is relatively sparse due to the brief introduction and subsequent abandonment of this agent. One double-blind randomized clinical trial comparing muraglitazar and pioglitazone found that the effects of the former were favourable in terms of HDL-C increase, decrease in total cholesterol, apolipoprotein B, triglycerides and a greater reduction in HbA1c (p <0.0001 for all comparisons). However, the muraglitazar group had a higher all-cause mortality, greater incidence of edema and heart failure and more weight gain compared to the pioglitazone group. A meta-analysis of the phase II and III clinical trials of muraglitazar revealed that it was associated with a greater incidence of myocardial infarction, stroke, transient ischemic attacks and congestive heart failure (CHF) when compared to placebo or pioglitazone.